1. Generics Bulletin
  2. >>Products
  3. >>Generics

Dr Reddy’s Accuses Amarin Of ‘Illegally’ Blocking Vascepa API Supply

Indian Firm Has Sued Originator In A New Jersey Court

 
• By Dean Rudge

Having sat on an approved Vascepa ANDA since August last year, Dr Reddy’s Laboratories has sued originator Amarin, claiming the firm has illegally cornered the market for the hard-to-manufacture active ingredient.

Competitive edge and business advantage concept as a group of hot air balloons racing to the top but an individualleader with a small balloon attached giving the winning competitor an extra boost.
Reddy's alleges that "illegal conduct" has given Amarin an unfair competitive edge • Source: Shutterstock

Dr. Reddy's Laboratories Ltd. says it would have launched its generic version of Amarin’s Vascepa (icosapent ethyl) in August last year but for the originator’s “illegal conduct to foreclose the supply” of the product’s active pharmaceutical ingredient.

The Indian firm has sued Amarin in a New Jersey district court, alleging violation of the antitrust Sherman Act over the company’s “anticompetitive conduct to delay and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

Lupin Touts FDA Approval For Generic Tolvaptan With 180-Day Exclusivity

 
• By Urtė Fultinavičiūtė

After receiving a favorable court ruling last year, Lupin has secured its first-place spot for generic tolvaptan tablets in the US.

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”